Dear Colleagues, It is with great pleasure that I introduce you to our new journal, Probiotics and Antimicrobial Proteins. The overall trend of the last few decades is obvious: there are fewer and fewer novel antibiotics being launched, and the resistance of human pathogens to commercially available drugs is on the rise. This remains a serious issue, with many cases of multiple drug resistance reported for Mycobacterium tuberculosis, Enterococcus spp., Salmonella, Escherichia coli, Campylobacter, etc.—not to mention several articles reporting on the ease of raising resistance to the drugs of choice in Bacillus anthracis. All of these factors have forced the international scientific community to search for new, effective antimicrobials. An increased understanding and acknowledgment of the role of healthy human probiota has placed the focus not on broad-spectrum antimicrobials with minimal side effects on the eukaryotic host but on antimicrobials that are specifically targeted against nondesired microorganisms that leave both healthy bacteria and the host alive and unharmed. These substances are ideally biodegradable, preferably nonimmunogenic, and available through cost-effective manufacturing processes. Many of the aforementioned features can be used to describe antimicrobial proteins which are produced by virtually all living creatures: histatins that are present in human saliva, defensins found in blood, plant defensins, cecropins from the Cecropia moth, magainins that were discovered in an African frog’s skin, and, of course, bacteriocins that are produced by microorganisms. These substances of a proteinaceous nature are ribosomally synthesized and serve as the first line of the host’s defense against intrusion into either its body or its ecological environment. This group of antimicrobials can be synergistically ‘‘joined’’ with secondary metabolites of a proteinaceous nature, such as e-poly-L-lysine that is produced by Streptomyces albulus, substances of a ‘‘mixed nature’’, such as lipopeptides. Common features among all of these molecules are that they are all naturally produced, and they all have protein (peptides) in the core of their structures. Most importantly, while their antimicrobial mechanisms of action are different from commercially available antibiotics, many of these proteins are also active against antibiotic-resistant bacteria. Taking into consideration all of the above, it is clear why there is a constant increase in papers published on antimicrobial proteins, and why the interest of the scientific community in these kinds of molecules is progressively growing.